151. Implications of ACC/AHA versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD
- Author
-
Vallejo-Vaz, Antonio J, Bray, Sarah, Villa, Guillermo, Brandts, Julia, Kiru, Gaia, Murphy, Jennifer, Banach, Maciej, De Servi, Stefano, Gaita, Dan, Gouni-Berthold, Ioanna, Kees Hovingh, G, Jozwiak, Jacek J, Jukema, J Wouter, Gabor Kiss, Robert, Kownator, Serge, Iversen, Helle K, Maher, Vincent, Masana, Luis, Parkhomenko, Alexander, Peeters, André, Clifford, Piers, Raslova, Katarina, Siostrzonek, Peter, Romeo, Stefano, Tousoulis, Dimitrios, Vlachopoulos, Charalambos, Vrablik, Michal, Catapano, Alberico L, Poulter, Neil R, Ray, Kausik K, DA VINCI Study Investigators, Experimental Vascular Medicine, Vascular Medicine, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Cardiac & Cardiovascular Systems ,STATIN THERAPY ,EZETIMIBE ,ATORVASTATIN ,Cardiovascular disease prevention ,CARDIOVASCULAR OUTCOMES ,DISEASE ,Pharmacology (medical) ,Pharmacology & Pharmacy ,LDL-C ,METAANALYSIS ,Pharmacology ,Science & Technology ,Lipid-lowering ,Statins ,DA VINCI Study Investigators ,General Medicine ,EFFICACY ,Cardiovascular risk ,SIMVASTATIN ,DENSITY-LIPOPROTEIN CHOLESTEROL ,Cardiovascular System & Hematology ,SAFETY ,Atherosclerotic cardiovascular disease ,Cardiovascular System & Cardiology ,lipids (amino acids, peptides, and proteins) ,1115 Pharmacology and Pharmaceutical Sciences ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine - Abstract
Purpose Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (vs. Methods DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of Results Of the 2039 patients, 61% did not achieve LDL-C Conclusion In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach. Graphical abstract
- Published
- 2022